Whalesbook
Novo Nordisk's India head, Vikrant Shrotriya, outlined the company's long-term strategy for India, prioritizing patient accessibility over sales volume. Key initiatives include a strategic 37% price cut for Wegovy to improve reach, an upcoming Ozempic launch within three months, and plans to manage competition post-semaglutide patent expiry by focusing on trust and quality. The company also highlighted its collaborations with Emcure Pharmaceuticals, Abbott, and Torrent Pharmaceuticals.